TeleDirectMD

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded GLP-1 medicationCompounded · not FDA-approved

What they publish

TeleDirectMD publishes 3 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Published ranges of $25 to $349 per month across programme types (as published)

Medication cost

Compounded medication published at often $150 to $400 per month (as published)

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

States manufacturer savings programmes from Novo Nordisk and Eli Lilly have changed the cost comparison.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Not publicly disclosed on the pages we captured.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Not publicly disclosed on the pages we captured.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Publishing analysis of FDA action that could restrict compounded GLP-1s is writing against its own commercial interest, which is worth crediting.
• Acknowledging that manufacturer savings programmes have 'changed the math' is an honest concession — the brand-versus-compounded gap has narrowed.
• The regulatory position on compounding is still moving; a provider tracking it publicly is at least engaging with the risk.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Regulatory change is a real risk if you prepay. Ask what happens to your money if the product cannot be supplied.
• Price the manufacturer self-pay channels before assuming compounded is cheaper.
• Ask which pharmacy compounds it and whether it is 503A or 503B.